Evec is a developer of a range of human monoclonal antibodies in multiple therapeutic areas, including cancer, inflammatory diseases and infectious diseases.
Astellas will pay a sum of JPY0.6bn as an upfront payment to Evec, under the license agreement.
Further, Astellas will also be responsible to pay milestone payments to Evec depending on development and sales phases totaling up to JPY13bn, as well as royalty payments related to potential product sales.